pdf1 Board of Directors Approves Company Participation in Recruitment Rounds at Company Holds CD’X and Cardiacsense Post published:02/12/2019
pdf1 CDX (held about 7.5%) FDA approval to test for prostate cancer as a breakthrough device Post published:22/10/2019
pdf1 A meeting convened for October 6, 2019 , is adjourned for November 5, 2019, in light of the company’s request Post published:06/10/2019
pdf1 Remedy (about 9.45%) has completed an inverted triple merger agreement with OptimizerX Post published:06/10/2019
